Results from the PROWESS trial suggested patients with a pulmonary cause of their sepsis to benefit more from systemic anticoagulation with recombinant human (rh)-activated protein C (APC) than patients with sepsis from another source [17-19]. The gene discussed is APC; the disease is Sepsis.